Limits...
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus

PCDH17 mRNA expression. A: 168 adjacent noncancerous tissues with unmethylated PCDH17; B: 64 tumors with unmethylated PCDH17; C: 127 tumors with methylated PCDH17; * P<0.05 (C vs. B or C vs. A).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588677&req=5

f4-medscimonit-21-2870: PCDH17 mRNA expression. A: 168 adjacent noncancerous tissues with unmethylated PCDH17; B: 64 tumors with unmethylated PCDH17; C: 127 tumors with methylated PCDH17; * P<0.05 (C vs. B or C vs. A).

Mentions: In order to certify that PCDH17 methylation was correlated with the down-regulation of its gene expression, quantitative real-time PCR was performed to detect the mRNA levels of PCDH17 in adjacent noncancerous tissues with unmethylated PCDH17, tumors with unmethylated PCDH17, and tumors with methylated PCDH17. We found that there was no difference between adjacent noncancerous tissues with unmethylated PCDH17 group and tumors with unmethylated PCDH17 group, but PCDH17 mRNA expression was significant lower in tumors with methylated PCDH17 group compared with the 2 groups with unmethylated PCDH17 mentioned above (P<0.05; Figure 4). The results indicate that PCDH17 methylation is associated with down-regulation of its expression.


Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

PCDH17 mRNA expression. A: 168 adjacent noncancerous tissues with unmethylated PCDH17; B: 64 tumors with unmethylated PCDH17; C: 127 tumors with methylated PCDH17; * P<0.05 (C vs. B or C vs. A).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588677&req=5

f4-medscimonit-21-2870: PCDH17 mRNA expression. A: 168 adjacent noncancerous tissues with unmethylated PCDH17; B: 64 tumors with unmethylated PCDH17; C: 127 tumors with methylated PCDH17; * P<0.05 (C vs. B or C vs. A).
Mentions: In order to certify that PCDH17 methylation was correlated with the down-regulation of its gene expression, quantitative real-time PCR was performed to detect the mRNA levels of PCDH17 in adjacent noncancerous tissues with unmethylated PCDH17, tumors with unmethylated PCDH17, and tumors with methylated PCDH17. We found that there was no difference between adjacent noncancerous tissues with unmethylated PCDH17 group and tumors with unmethylated PCDH17 group, but PCDH17 mRNA expression was significant lower in tumors with methylated PCDH17 group compared with the 2 groups with unmethylated PCDH17 mentioned above (P<0.05; Figure 4). The results indicate that PCDH17 methylation is associated with down-regulation of its expression.

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus